# Akero Therapeutics (stock symbol: AKRO) Logo in transparent PNG and SVG formats

## Akero Therapeutics Logo large

### Akero Therapeutics Logo large Download PNG (31.56 KB)

![Akero Therapeutics Logo large Download PNG (31.56 KB)](/img/orig/AKRO_BIG-6f0317ed.png)

### Akero Therapeutics Logo large Download SVG (2.02 KB)

![Akero Therapeutics Logo large Download SVG (2.02 KB)](/img/orig/AKRO_BIG-1d1a97e8.svg)

## Akero Therapeutics Logo icon format

### Akero Therapeutics Logo icon format Download PNG (24.88 KB)

![Akero Therapeutics Logo icon format Download PNG (24.88 KB)](/img/orig/AKRO-1c5d53e3.png)

### Akero Therapeutics Logo icon format Download SVG (756 Bytes)

![Akero Therapeutics Logo icon format Download SVG (756 Bytes)](/img/orig/AKRO-150a85fd.svg)

## Akero Therapeutics Logo large for dark backgrounds

### Akero Therapeutics Logo large for dark backgrounds Download PNG (33.14 KB)

![Akero Therapeutics Logo large for dark backgrounds Download PNG (33.14 KB)](/img/orig/AKRO_BIG.D-40b81d16.png)

### Akero Therapeutics Logo large for dark backgrounds Download SVG (1.82 KB)

![Akero Therapeutics Logo large for dark backgrounds Download SVG (1.82 KB)](/img/orig/AKRO_BIG.D-3873b769.svg)

## Akero Therapeutics Logo icon format for dark backgrounds

### Akero Therapeutics Logo icon format for dark backgrounds Download PNG (23.75 KB)

![Akero Therapeutics Logo icon format for dark backgrounds Download PNG (23.75 KB)](/img/orig/AKRO.D-732a94a1.png)

### Akero Therapeutics Logo icon format for dark backgrounds Download SVG (756 Bytes)

![Akero Therapeutics Logo icon format for dark backgrounds Download SVG (756 Bytes)](/img/orig/AKRO.D-b22ede10.svg)

## About Akero Therapeutics

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

1. Website domain: akerotx.com
2. Employees: 37
3. Marketcap: $2.10 Billion USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
